News | Stents Drug Eluting | October 26, 2015

One-Year Outcomes from Combo REMEDEE All-Comers Registry Presented at TCT 2015

Study results demonstrate clinical effectiveness of OrbusNeich’s Combo dual therapy stent in one-year target lesion failure

REMEDEE Registry, one-year outcomes, Combo dual therapy stent, OrbusNeich, TCT 2015

October 26, 2015 — OrbusNeich announced the presentation of the one-year clinical outcomes from the 1,000-patient REMEDEE Registry at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) meeting, Oct. 11-15 in San Francisco. Data was presented by Robbert de Winter, M.D., Ph.D., of the Academic Medical Center, Amsterdam and principal investigator of the study.

The REMEDEE Registry is designed to evaluate the safety and performance of the Combo Dual Therapy Stent for the treatment of coronary lesions in the routine clinical care setting. Patients were enrolled from nine European high-volume percutaneous coronary intervention (PCI) centers.

The registry’s primary endpoint of one-year target lesion failure (TLF) was reported at the incidence of 5.7 percent; TLF is defined as an independently adjudicated hierarchical composite of cardiac death (CD), target vessel myocardial infarction (TV-MI) not clearly attributable to a non-target vessel or target lesion revascularization (TLR) by PCI or by coronary artery bypass grafting (CABG). The individual cardiac event rates reported were 1.7 percent CD, 0.7 percent TV-MI and 4.4 percent ischemia-driven TLR. The registry also showed a very low stent thrombosis rate of 0.6 percent. There was no incidence of late stent thrombosis; all thrombotic events occurred within the first 9 days after implant.

The REMEDEE registry is a true ‘All Comers’ study with patient risk factors that include 18.4 percent diabetics, 58 percent hypertension, 56.2 percent hypercholesterolemia and 37 percent prior revascularization. Thirty percent of the patients presented with acute coronary Syndrome (ACS), comprised of ST-elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI) and unstable angina, whilst an additional 10 percent of the patients had stabilized ACS. Of the lesions treated, 50 percent were of type B2 and C.

“The one-year outcomes have provided real-world insights that support clinical effectiveness and safety of Combo in terms of low ischemic and thrombotic event rates,” said de Winter.

Other data showcased at TCT 2015 included highlights of the clinical trial program for Combo. During the Didactic Symposia Session focusing on the latest metallic drug-eluting stent (DES) technology, an update on the HARMONEE trial was presented in support of the company’s planned application for Combo approval in Japan and the United States. “With enrollment well under way, we are looking forward to evaluating for the first time how both physiologic and anatomic measures can assess long-term outcomes, as well as using the most technologically advanced high-resolution imaging to show vascular healing,” said Roxana Mehran, M.D., director of interventional cardiovascular research and clinical trials, Mount Sinai Medical Center.

Prof. Stephen W.L. Lee, M.D., of the Queen Mary Hospital, Hong Kong, also presented two-year optical coherence tomography (OCT) findings and three-year clinical follow-up from the EGO-COMBO study. The results supported Combo’s early healing benefits, with a near 80 percent coverage at 2 months. Stability in the long-term was also observed with progressive neointimal maturation without development of late stent failure up to three years. More importantly, significant neointimal regression was observed from 9 to 24 months, a phenomenon unseen with conventional metallic DES.

For more information:

Related Content

Videos | TCT | October 03, 2018
DAIC Editor Dave Fornell takes a tour of some of the most innovative new cardiovascular technology he found on the ex
cardiologist Ted Feldman, M.D., at TCT 2017. #TCT2018 #TCT #TCT18 TCT Late breaking trials, studies.
Feature | TCT | September 21, 2018
October 4, 2018 – The Cardiovascular Research Foundation (CRF) had 15 late-breaking trials and 12 late-breaking clini
Interventional cardiology, cath lab technology, TCT, transcatheter cardiovascular therapeutics. #TCT #TCT18 #TCT2018
Feature | TCT | September 14, 2018 | Dave Fornell, Editor
The volume of information attendees receive at the annual...
Videos | TCT | November 15, 2017
DAIC Editor Dave Fornell shows some of the innovations displayed on the expo floor at the 2017 Transcatheter Cardiova
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | TCT | November 09, 2017
November 9, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has select
Key Interventional Cardiology and structural heart Technologies to Prepare for TCT 2017.
Feature | TCT | October 26, 2017 | Dave Fornell
Here is an aggregation of DAIC content for all major cardiovascular technology news and advances this past year. These...
Videos | TCT | November 18, 2016
DAIC Editor Dave Fornell takes a video tour of some of the most innovative new interventional cardiology technologies
Videos | TCT | November 05, 2015
DAIC Editor Dave Fornell offers his choices for the most innovative new interventional cardiovascular technologies pr
Videos | TCT | November 05, 2015
Tom Watson, clinical analyst for MDBuyLine, and DAIC Dave Fornell discuss some of the technology trends at the 2015 T
Amaranth Fortitute Bioresorbable stent

The Amaranth Fortitute bioresorbable stent was among several fully bioresorbing platforms discussed in sessions, late breaking trial data presentations and on the expo floor at TCT 2015.

Feature | TCT | October 19, 2015 | Tom Watson, BS, RCVT, Clinical Analyst, MD Buyline
There were several overarching technology trends seen at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) ann
Overlay Init